Canine osteosarcoma: amputation and chemoimmunotherapy.
Canine osteosarcoma is a highly metastatic cancer commonly seen in large breed dogs. At the time of diagnosis, approximately 90% to 95% of the dogs have established micrometastases. Dogs undergoing amputation alone have a median survival time of 3 to 4 months. Amputation followed by cisplatin chemotherapy increases median survival times to 9 to 11 months. When dogs are treated with amputation and cisplatin, followed by immunotherapy (with liposome-encapsulated muramyl tripeptide phosphatidylethanolamine), median survival times increase to 14.4 months, the longest reported median survival time for dogs with osteosarcoma treated by amputation and any form of adjuvant therapy.
MacEwen
E G
EG
Department of Medical Sciences, University of Wisconsin, Madison 53706, USA.
Kurzman
I D
ID
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000592:standards / Q000627:therapeutic use; D000671:Amputation, Surgical / Q000592:standards / Q000662:veterinary*; D000818:Animals; D000970:Antineoplastic Agents / Q000592:standards / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000601:surgery / Q000628:therapy / Q000662:veterinary*; D002945:Cisplatin / Q000592:standards / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000592:standards / Q000662:veterinary; D004283:Dog Diseases / Q000188:drug therapy / Q000601:surgery* / Q000628:therapy*; D004285:Dogs; D004359:Drug Therapy, Combination; D007167:Immunotherapy / Q000592:standards / Q000662:veterinary*; D012516:Osteosarcoma / Q000601:surgery / Q000628:therapy / Q000662:veterinary*; D010714:Phosphatidylethanolamines / Q000592:standards / Q000627:therapeutic use
D000970:Antineoplastic Agents; D010714:Phosphatidylethanolamines; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D002945:Cisplatin